PHARMACY PROFESSIONS IN INDIADURING COVID-19 PANDEMIC: PRESENT STATUS, FUTURE CHALLENGES AND A WAY FORWARD
People in every country became exposed to COVID-19 pandemic and cannot able to find a right solution and strategies to overcome from it. Pharmacy is the most important, dynamic and versatile health care profession in the world, whereas its scope and importance are always being emerging at any situation. Pharmacy professionals (PPs) working proactively for the public even in this pandemic situation. Since dependency is high, the responsibility and preference also high for PPs especially in this pandemic situation. Current status in pharmacy education and emerging future challenges of PPs in all aspects, particularly in thispandemic situation were addressed based on observational studies among various pharma industries and published news of Pharmacy Council of India (PCI). While in the development phase it has crossed many barriers, not only in the economic level,but also involves regulations, duration, process controls, legal hurdles and situational defects. The purpose of this review discusses the evolution and updates in pharmacy, education, pharmacy practice, regulations, and types of challenges along with recommendations for PPs in India in light of the COVID-19 pandemic.
This review was carried out to summarize knowledge about the updates and challenges in pharmacy professions in all aspects. Sources were retrieved from relevant guidelines and published articles in Google scholar, Pubmed and Science direct of articles up to June 2020. The keywords used for gathering information were listed below.
2. Basak SC, Sathyanarayana D. Community pharmacy practice in India: past, present and future. South Med Rev 2009;2:11-4.
3. Rotta I, Salgado TM. Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. J Evaluation Clin Practice 2015;21:584-90.
4. Mohanan M, Hay K, Mor N. Quality of health care in India: challenges, priorities, and the road ahead. Health Affairs2016;35:1753-8.
5. MoHFW. Home; 2020. Available from: https://www.mohfw.gov.in/. 05 Aug 2020]
6. Lakshminarayanan S. Role of government in public health: current scenario in India and future scope. J Family Community Med 2016;18:26-30.
7. Kalaiselvan V, Srivastava S, Singh A. Pharmacovigilance in India: present scenario and future challenges. Drug Safety 2019;42:339-46.
8. Palsokar G, Tajne M. Postgraduate research in pharmaceutical sciences in India: a survey of select pharmacy professionals. Int J Curr Pharm Res 2017;9:161-4.
9. Jose J, Rafeek N. Rpharmacovigilance in India in comparison with the USA and European Union: challenges and perspectives. Ther Innovation Regulatory Sci 2019;53:781-6.
10. Mohanan M, Hay K, Mor N. Quality of health care in India: challenges, priorities, and the road ahead. Health Affairs2016;35:1753-8.
11. Vignesh M, Ganesh GNK. Current status, challenges and preventive strategies to overcome data integrity issues in the pharmaceutical industry. Int J Appl Pharm 2020;12:19-23.
12. Supreme court of India, Union of India vs. M. V. Mohanan Nair; 2020. Available from: https://indiankanoon.org/doc/55062525/[Last accessed on 05 Aug 2020]
13. Kishore J. Legislation and health promotion in India. Rev Global Med Healthcare Res 2012;37:75-87.
14. RamalingamPeraman, Hari Hara ThejaDugga. Need for the refinement of licensing procedure for pharmacists in India. J Young Pharm 2016;8:293.
15. Lakshminarayanan S. Role of government in public health: current scenario in India and future scope. JFamily Community Med 2016;18:26-30.
16. Peter Roderick, Rushikesh Mahajan.India should introduce a new drugs act. Lancet2014;383:203-6.
17. Daniel Bennett, Wesley Yin. The market for high-quality medicine: retail chain entry and drug quality in India. Rev Economics Statistics 2019;101:76-90.
18. Thaker Z, Jethva K, Bhatt D, Zaveri M, Deshpande S. Orphan drugs: overview and regulatory review process. Int J Pharm Sci Res 2019;10:505-18.
19. Agarwal Praveen, Bhandary Deepak, Rasheed Abdul. Drug approval procedure in India (CDSCO). Res Rev: J Drug Design Discovery2015;2:20-6.
20. Daniel Bennett, Wesley Yin. The market for high-quality medicine: retail chain entry and drug quality in India. Rev Economics Statistics 2019;101:76-90.
21. PravatKumar J. Impact of pandemic COVID-19 on education in India. Int J Curr Res 2020;12:12582-6.
22. World Health Organization. Coronavirus disease (COVID-19) outbreak situation; 2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavir us-2019. [Last accessed on 10 Aug 2020].
23. Hedima EW, Adeyemi MS, Ikunaiye NY. Community pharmacists: on the frontline of health service against COVID-19 in LMICs. Res Soc Administrative Pharm 2020;19:30381-8.
24. Carolina Oi Lam Ung. Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreak. Res SocAdministrative Pharm 2020;16:583-6.
25. Mukattash TL, Jarab AS. Pharmacists’ perception of their role during COVID-19:a qualitative content analysis of posts on facebook pharmacy groups in Jordan. Pharm Practice 2020;18:1900.
26. Shrimali, Gireesh, Retna Kumar, Aravind. Battery storage manufacturing in India: a strategic perspective; 2020. Available from: https://ssrn.com/abstract=3616404[Last accessed on 10 Aug 2020]
27. Usha Sharma. Pharmacos should develop strategies to develop APIs and making India self-reliant: Dr Eswara Reddy. Express pharma; 2020. Available from: https://www.expresspharma.in/latest-updates/pharma-cos-should-develop-strategies-to-develop-apis-and-making-india-self-reliant-dr-eswara-reddy/[Last accessed on 10 Aug 2020]
28. Department of pharmaceuticals. PLI Scheme for Pharmaceuticals and Medical devices; 2020. Available from: https://pharmaceuticals.gov.in/schemes#:~:text=Download%20(1.6%20MB)-,Production%20Linked%20Incentive%20(PLI)%20Scheme%20for%20promotion%20of%20domestic%20manufacturing,Promotion%20of%20Bulk%20Drug%20Parks.[Last accessed on 10 Aug 2020]
29. MansukhMandaviya. Covid-19: centre chalks out four schemes to boost production of bulk drugs and medical devices; 2020. Available from: https://economictimes.indiatimes.com/news/economy/policy/covid-19-centre-chalks-out-four-schemes-to-boost-production-of-bulk-drugs-and-medical-devices/articleshow/74867468.cms?from=mdr [Last accessed on 10 Aug 2020]
30. Anyachebelu O, Aluh D. Pharmacists compliance to practice regulations and good professional practice: a case study of Nigerian community pharmacists. Int J Pharm PharmSci2018;10:98-104.
31. Shahrawat R, Rao KD. Insured yet vulnerable: out-of-pocket payments and India’s poor. Health Policy Plan 2012;27:213-21.
32. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatrics 2020;87:281-6.
33. Mackey. Fit-for-purpose?-challenges and opportunities for applications of blockchain technology in the future of healthcare. BMC Med 2019;17:1-17.
34. Vignesh M,Ganesh GNK.Fixed dose combinations banned in India-a review.J Pharm Sci Res 2020;12:987-91.
35. Aiswarya Vijayan. Digital India-a roadmap to sustainability. Int J Innovative Technol Exploring Engineering2019;8:571-6.
36. Nedungadi PP, Menon R, Gutjahr G, Erickson L, Raman R. Towards an inclusive digital literacy framework for digital India. EducationTraining2018;60:516-28.
37. Snyder ME, Jaynes HA. Factors associated with comprehensive medication review completion rates: a national survey of community pharmacists. Res Soc Administrative Pharm 2020;16:673-80.
38. Rajubhai L Pargi. Implication and impact of digital education system in India. Int J Humanities SocSci: Insights Transformations 2019;4:1-6.
39. Vignesh M, Ganesh GNK. Generic prescription in India-a review. Asian J Pharm Clin Res 2020;13:20-4.
40. Nandini G, Anitha K. An intelligent pharmacy and health care services. J Critical Rev 2020;7:1820-6.
This work is licensed under a Creative Commons Attribution 4.0 International License.